EUCTR2020-001168-28-BG进行中（未招募）1 期
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 736
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age 18-55 years
- •Expanded Disability Status Scale score (EDSS) of 0.0-5.5 at screening
- •A diagnosis of RMS in accordance with the revised 2017 McDonald Criteria
- •Neurologically stable for at least 30 days prior to randomization and baseline assessments
- •Ability to complete the 9-HPT for each hand in < 240 seconds
- •Ability to perform the timed 25-Foot Walk Test in <150 seconds
- •For women of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs, women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period, for 8 weeks after the final dose of study medication, and until the teriflunomide elimination protocol is completed
- •For men: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm, with a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment phase, for 8 weeks after the final dose of study drug, and until completion of the teriflunomide elimination protocol. Men must also refrain from donating sperm during this same period
- •OLE Inclusion Criteria:
- •Completed the Double-Blind Treatment (DBT) phase of the study (remaining on study treatment; no other Disease-Modifying Therapy (DMT) administered) and who, in the opinion of the investigator, may benefit from treatment with fenebrutinib
- •Patients randomized to the teriflunomide treatment arm during the DBT phase must undergo the ATEP prior to the first administration of open-label fenebrutinib
- •For female participants of childbearing potential: agreement to remain abstinent or use contraception, and agreement to refrain from donating eggs, women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period, the OLE treatment phase and for 28 days after the final dose of open-label fenebrutinib. Women must also refrain from donating eggs during this same period
- •For male participants: agreement to remain abstinent or use a condom, and agreement to refrain from donating sperm, with a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment phase, OLE treatment phase and for 28 days after the final dose of open-label fenebrutinib to avoid exposing the embryo. Men must also refrain from donating sperm during this same period.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 736
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •A diagnosis of PPMS or non-active SPMS
- •Disease duration of > 10 years from the onset of symptoms and an EDSS score at screening < 2.0
- •Any known or suspected active infection at screening or baseline, or any major episode of infection requiring hospitalization or treatment with IV anti-microbials within 8 weeks prior to and during screening or treatment with oral anti-microbials within 2 weeks prior to and during screening. Onychomycosis is not exclusionary unless it is being treated with systemic therapy
- •History of cancer including hematologic malignancy and solid tumors within 10 years of screening.
- •Known presence of other neurological disorders that could interfere with the diagnosis of MS or assessments of efficacy or safety during the study, clinically significant cardiovascular, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic or gastrointestinal disease
- •Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
- •History of alcohol or other drug abuse within 12 months prior to screening
- •Any previous treatment with immunomodulatory or immunosuppressive medication without an appropriate washout period
- •Receipt of a live or live-attenuated vaccine within 6 weeks prior to randomization
- •Female participants who are pregnant or breastfeeding or intending to become pregnant during the study or 8 weeks (with ATEP) after final dose of study drug
- •Male participants intending to father a child during the study or 8 weeks (with ATEP) after final dose of study drug
- •Presence of cirrhosis (Child-Pugh Class A, B, or C) or Gilbert’s Syndrome
研究者
相似试验
尚未招募
不适用
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND,DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATETHE EFFICACY AND SAFETY OF FENEBRUTINIB COMPAREDWITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSISMultiple sclerosis-G35 Multiple sclerosisG35PER-076-20F. HOFFMANN-LA ROCHE LTD.,
进行中（未招募）
1 期
To Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple SclerosisRelapsing multiple sclerosis (RMS)MedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 27.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-004857-10-PTF. Hoffmann-La Roche Ltd736
进行中（未招募）
1 期
To Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple SclerosisRelapsing multiple sclerosis (RMS)MedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 27.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-004857-10-DEF. Hoffmann-La Roche Ltd736
进行中（未招募）
1 期
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-004128-41-GRF. Hoffmann-La Roche Ltd171
进行中（未招募）
1 期
To Evaluate the Efficacy and Safety of Fenebrutinib Compared with Teriflunomide in Adult Patients with Relapsing Multiple SclerosisRelapsing multiple sclerosis (RMS)MedDRA version: 20.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.0Level: PTClassification code 10080700Term: Relapsing multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2019-004857-10-HUF. Hoffmann-La Roche Ltd736